Tsubota Laboratory: Announcements of individual stocks relating to relocation of headquarters.
Tsubota Laboratory: Announcements of individual stocks regarding the publication of the research paper "Establishment of in vitro choroidal complex for vascular response screening"
Tsubota Laboratory: A report on the preliminary clinical trial results for TLG-005 targeting depression.
Tsubota Laboratory: Announcement of preliminary results of specific clinical study of TLG-005 targeting Parkinson's disease.
Tsubota Laboratory: Our representative, Kazuo Pingda, has been appointed as a visiting professor of ophthalmology at Wenzhou Medical University.
Tsubota Laboratory: A Japanese company has opened an office for the first time in Eye Valley, Wenzhou, Zhejiang Province.
Tsubota Laboratory: Regarding matters related to dominant shareholders.
Tsubota Laboratory: About the license agreement in the American continent related to TLG-001.
Tsubota Laboratory: Matters related to business plans and growth potential.
Tsubota Laboratory: Completion of the TLG-005 (Parkinson's disease) project with Sumitomo Pharma Co., Ltd. and future research policies
Tsubota Laboratory: Presented 16 abstracts at the 6th Annual Meeting of the Japanese Myopia Society
Tsubota Laboratory: 14 research results announced at ARVO2024
Tsubota Laboratory: Notice of completion of inclusion of subjects in specific clinical research on mild dementia (MCI) of the pipeline “TLG-005”
Tsubota Laboratory: Adoption as a grant project in the Reiwa 5 Femtech Development Support/Dissemination Promotion Project for Women
Tsubota Lab: Notice regarding the conclusion of an intellectual property license agreement with Rohto Pharmaceutical Co., Ltd.
Tsubota Lab: Adoption for the Reiwa 5 TOKYO Strategic Innovation Promotion Project as a grant project
Tsubota Laboratory: Notice regarding the presentation of the research paper “Deceleration in eye axis lengthening in response to the COVID-19 pandemic due to the increase in time spent outdoors”
Tsubota Laboratory: Notice about specific clinical research on the pipeline “TLM-007”
Tsubota Laboratory: Notice regarding cancellation of basic agreement agreement with Santen Pharmaceutical Co., Ltd.
Tsubota Laboratory: Presentation of a paper by Keio University Medical School on the safety of long-term administration of the anti-aging candidate substance NMN in healthy adults
No Data